Skip to content

Study · Randomized controlled trial · 2014

8 results

Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers.

Gurkan E, Tarkun I, Sahin T, Cetinarslan B, Canturk Z

Diabetes research and clinical practice7 Oct 2014Cited by 33 (Europe PMC)

PMID25458329 (opens in a new tab)DOI10.1016/j.diabres.2014.09.046 (opens in a new tab)PepBankPUB-25458329
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, high sensitivity C-reactive protein decreased by 27.5% in the exenatide arm.

    In plain wordsIn patients with diabetes, C-reactive protein decreased by 27.5% with exenatide compared with baseline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHigh sensitivity C-reactive protein
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    hs-CRP decrease
    27.5%
    exenatide arm

    Source sentences

    Summary
    Levels of high sensitivity-C-reactive protein and endothelin-1 decreased (27.5% and 18.75%, respectively) in the exenatide arm.
    1 context sentence
    Summary · context
    Thirty-four insulin and incretin-naive patients with type 2 diabetes mellitus (body mass index 25-45 kg/m(2)) who received metformin for at least two months were randomized to exenatide or insulin glargine treatment arms and followed-up for 26 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, endothelin-1 decreased by 18.75% in the exenatide arm.

    In plain wordsIn patients with diabetes, endothelin-1 decreased by 18.75% with exenatide compared with baseline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseEndothelin-1
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    Endothelin-1 decrease
    18.75%
    exenatide arm

    Source sentences

    Summary
    Levels of high sensitivity-C-reactive protein and endothelin-1 decreased (27.5% and 18.75%, respectively) in the exenatide arm.
    1 context sentence
    Summary · context
    Thirty-four insulin and incretin-naive patients with type 2 diabetes mellitus (body mass index 25-45 kg/m(2)) who received metformin for at least two months were randomized to exenatide or insulin glargine treatment arms and followed-up for 26 weeks.

Studies that did not test the peptide alone6

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 03HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In patients with diabetes, flow-mediated dilatation increased in both exenatide and insulin glargine arms.

    In plain wordsBlood vessel dilation improved in both treatment groups, including exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseFlow-mediated dilatation
    Study

    n = 34

    Comparator
    Baseline
    Outcome group
    Vascular function · Cardiovascular

    Source sentences

    Summary
    Post-treatment flow mediated dilatation and endothelium independent vascular responses were significantly higher in both arms (p=0.0001, p=0.0001).
    1 context sentence
    Summary · context
    Thirty-four insulin and incretin-naive patients with type 2 diabetes mellitus (body mass index 25-45 kg/m(2)) who received metformin for at least two months were randomized to exenatide or insulin glargine treatment arms and followed-up for 26 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 04HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In patients with diabetes, endothelium-independent vascular responses increased in both exenatide and insulin glargine arms.

    In plain wordsVessel responses independent of the vessel lining improved in both groups, including exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseEndothelium-independent vascular response
    Study

    n = 34

    Comparator
    Baseline
    Outcome group
    Vascular function · Cardiovascular

    Source sentences

    Summary
    Post-treatment flow mediated dilatation and endothelium independent vascular responses were significantly higher in both arms (p=0.0001, p=0.0001).
    1 context sentence
    Summary · context
    Thirty-four insulin and incretin-naive patients with type 2 diabetes mellitus (body mass index 25-45 kg/m(2)) who received metformin for at least two months were randomized to exenatide or insulin glargine treatment arms and followed-up for 26 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 05HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialOther

    In both diabetes treatment arms, weight change correlated positively with endothelium-independent vasodilatation change.

    In plain wordsIn both groups, weight change was positively linked to change in vessel dilation independent of the vessel lining.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableWeight and endothelium-independent vasodilatation correlation
    Study

    n: not reported in source

    Outcome group
    Vascular function · Cardiovascular

    Measurements

    Correlation coefficient (r)
    0.376 r
    change in body weight vs change in endothelium-independent vasodilatation, both arms

    Source sentences

    Summary
    Positive correlation was observed between the changes in body weight and endothelium-independent vasodilatation, leptin, plasminogen activator inhibitor type 1 and endothelin-1 in both arms (r=0.376, r=0.507, r=0.490, r=0.362, respectively).
    1 context sentence
    Summary · context
    Thirty-four insulin and incretin-naive patients with type 2 diabetes mellitus (body mass index 25-45 kg/m(2)) who received metformin for at least two months were randomized to exenatide or insulin glargine treatment arms and followed-up for 26 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  4. 06HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialOther

    In both diabetes treatment arms, weight change correlated positively with leptin change.

    In plain wordsIn both groups, weight change was positively linked to leptin change.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableWeight and leptin correlation
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Measurements

    Correlation coefficient (r)
    0.507 r
    change in body weight vs change in leptin, both arms

    Source sentences

    Summary
    Positive correlation was observed between the changes in body weight and endothelium-independent vasodilatation, leptin, plasminogen activator inhibitor type 1 and endothelin-1 in both arms (r=0.376, r=0.507, r=0.490, r=0.362, respectively).
    1 context sentence
    Summary · context
    Thirty-four insulin and incretin-naive patients with type 2 diabetes mellitus (body mass index 25-45 kg/m(2)) who received metformin for at least two months were randomized to exenatide or insulin glargine treatment arms and followed-up for 26 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  5. 07HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialOther

    In both diabetes treatment arms, weight change correlated positively with plasminogen activator inhibitor type 1 change.

    In plain wordsIn both groups, weight change was positively linked to change in plasminogen activator inhibitor type 1.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableWeight and plasminogen activator inhibitor type 1 correlation
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Measurements

    Correlation coefficient (r)
    0.49 r
    change in body weight vs change in plasminogen activator inhibitor type 1, both arms

    Source sentences

    Summary
    Positive correlation was observed between the changes in body weight and endothelium-independent vasodilatation, leptin, plasminogen activator inhibitor type 1 and endothelin-1 in both arms (r=0.376, r=0.507, r=0.490, r=0.362, respectively).
    1 context sentence
    Summary · context
    Thirty-four insulin and incretin-naive patients with type 2 diabetes mellitus (body mass index 25-45 kg/m(2)) who received metformin for at least two months were randomized to exenatide or insulin glargine treatment arms and followed-up for 26 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  6. 08HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialOther

    In both diabetes treatment arms, weight change correlated positively with endothelin-1 change.

    In plain wordsIn both groups, weight change was positively linked to endothelin-1 change.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableWeight and endothelin-1 correlation
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Measurements

    Correlation coefficient (r)
    0.362 r
    change in body weight vs change in endothelin-1, both arms

    Source sentences

    Summary
    Positive correlation was observed between the changes in body weight and endothelium-independent vasodilatation, leptin, plasminogen activator inhibitor type 1 and endothelin-1 in both arms (r=0.376, r=0.507, r=0.490, r=0.362, respectively).
    1 context sentence
    Summary · context
    Thirty-four insulin and incretin-naive patients with type 2 diabetes mellitus (body mass index 25-45 kg/m(2)) who received metformin for at least two months were randomized to exenatide or insulin glargine treatment arms and followed-up for 26 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.